BioCentury | Feb 3, 2017
Financial News

Cantabio completes private placement of convertible debentures

...On Feb. 2, neurodegenerative disease company Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) raised $300,000 in debentures in the first tranche...
...a 7% discount to the market, with a floor of $0.10. Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), Sunnyvale, Calif. Alicia Parker Cantabio Pharmaceuticals Inc....
BioCentury | Oct 20, 2016
Product R&D

Chaperoning the DJ

...In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the...
...α-synuclein (SNCA); DJ-1 (PARK7). Source: Cantabio Pharmaceuticals Inc. Toth told BioCentury the chaperones are the “backbone of Cantabio’s...
...DJ-1 function Development status Preclinical Patents Patent application filed Company Cantabio Pharmaceuticals Inc. Companies and Institutions Mentioned Cantabio Pharmaceuticals Inc....
BioCentury | Aug 1, 2016
Company News

Cantabio, Purdue University deal

...disease (PD). Cantabio will have access to resulting IP. Cantabio declined to disclose financial terms. Cantabio Pharmaceuticals Inc....
BioCentury | Jun 27, 2016
Company News

Cantabio, University of Antioquia deal

...Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting...
...DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partners are focusing on protective effects of Cantabio’s...
...and cellular signaling mechanisms on neuron-like cell models. The partners did not respond to inquiries. Cantabio Pharmaceuticals Inc....
Items per page:
1 - 4 of 4
BioCentury | Feb 3, 2017
Financial News

Cantabio completes private placement of convertible debentures

...On Feb. 2, neurodegenerative disease company Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) raised $300,000 in debentures in the first tranche...
...a 7% discount to the market, with a floor of $0.10. Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), Sunnyvale, Calif. Alicia Parker Cantabio Pharmaceuticals Inc....
BioCentury | Oct 20, 2016
Product R&D

Chaperoning the DJ

...In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the...
...α-synuclein (SNCA); DJ-1 (PARK7). Source: Cantabio Pharmaceuticals Inc. Toth told BioCentury the chaperones are the “backbone of Cantabio’s...
...DJ-1 function Development status Preclinical Patents Patent application filed Company Cantabio Pharmaceuticals Inc. Companies and Institutions Mentioned Cantabio Pharmaceuticals Inc....
BioCentury | Aug 1, 2016
Company News

Cantabio, Purdue University deal

...disease (PD). Cantabio will have access to resulting IP. Cantabio declined to disclose financial terms. Cantabio Pharmaceuticals Inc....
BioCentury | Jun 27, 2016
Company News

Cantabio, University of Antioquia deal

...Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting...
...DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partners are focusing on protective effects of Cantabio’s...
...and cellular signaling mechanisms on neuron-like cell models. The partners did not respond to inquiries. Cantabio Pharmaceuticals Inc....
Items per page:
1 - 4 of 4